ICER Weekly View 03-31-17
From the review:
Democrats’ New Drug Bill
Improving Access to Affordable Prescription Drugs Act was introduced this week. You can read the summary of the bill here. Rachel Sachs takes a deep dive into the significance of the different provisions here. [...]
Looking forward, part of his focus will be on approving “complex generics” faster (loosely defined as involving a drug and delivery device). And finally, Amitabh Chandra, Ph.D., and Rachel E. Sachs, J.D., M.P.H. look at the challenges he will face: An FDA Commissioner for the 21st Century
Read more of the review here! Check out Rachel Sachs' Bill of Health blog post here and her NEJM article here!
Read the full review here
Read Rachel Sachs' blog post
Read Rachel Sachs' NEJM article
Tags
biotechnology fda health care finance health law policy pharmaceuticals rachel sachs regulation